Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Rating of “Moderate Buy” by Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $131.20.

A number of research firms have commented on LNTH. Wall Street Zen upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. B. Riley reduced their target price on Lantheus from $122.00 to $109.00 and set a “buy” rating on the stock in a report on Monday, June 23rd. William Blair restated a “market perform” rating on shares of Lantheus in a report on Wednesday, July 16th. Finally, Truist Financial dropped their price target on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th.

Lantheus Stock Performance

NASDAQ LNTH opened at $70.57 on Friday. Lantheus has a fifty-two week low of $69.12 and a fifty-two week high of $118.21. The stock has a market cap of $4.88 billion, a PE ratio of 20.05 and a beta of 0.14. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74. The firm’s fifty day moving average price is $77.65 and its two-hundred day moving average price is $87.98.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The business had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same quarter last year, the company posted $1.69 earnings per share. The company’s revenue was up .8% compared to the same quarter last year. On average, equities analysts expect that Lantheus will post 6.01 EPS for the current fiscal year.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares in the company, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

Several large investors have recently made changes to their positions in the company. State of Michigan Retirement System raised its holdings in Lantheus by 0.6% during the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider’s stock worth $1,620,000 after buying an additional 100 shares during the last quarter. Signaturefd LLC raised its holdings in shares of Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 116 shares during the last quarter. Intrust Bank NA raised its holdings in shares of Lantheus by 2.9% in the 1st quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider’s stock worth $431,000 after acquiring an additional 125 shares during the last quarter. Foundry Partners LLC lifted its position in Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 133 shares in the last quarter. Finally, Focus Financial Network Inc. boosted its stake in Lantheus by 4.0% during the 2nd quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider’s stock valued at $293,000 after purchasing an additional 136 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.